News
LABT ▲ +10.6% - Lakewood-Amedex Biotherapeutics, Inc.
LABT ▲ +10.6% - Lakewood-Amedex Biotherapeutics, Inc.
$LABT - Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
24-SEP-2026 08:02 AM ET
Share this post
More filings for $LABT
LABT ▲ +12.6% - Lakewood-Amedex Biotherapeutics, Inc.Sep 21, 2026LABT ▲ +5.3% - Lakewood-Amedex Biotherapeutics, Inc.Sep 18, 2026LABT ▲ +1.1% - Lakewood-Amedex Biotherapeutics, Inc.Sep 8, 2026LABT ▲ +47.8% - Lakewood-Amedex Biotherapeutics, Inc.Aug 31, 2026LABT ▲ +47.8% - Lakewood-Amedex Biotherapeutics, Inc.Aug 31, 2026LABT ▲ +47.8% - Lakewood-Amedex Biotherapeutics, Inc.Aug 31, 2026
View full $LABT filing history →💬 Comments
Loading comments…
Leave a comment